WuXi adds plants to Changzhou complex

WuXi STA, the pharmaceutical contract services division of WuXi AppTec, has expanded oligonucleotide and peptide manufacturing with a new large-scale facility at its Changzhou, China, complex. The 2,840 m² oligonucleotide plant includes four large-scale production lines and more than 20 smaller units, increasing the capacity for a single synthesis run from 1.9 mol to 6.0 mol. The 2,068 m² peptide plant features three production lines with reactors that accommodate up to 1,000 L, increasing WuXi’s total reactor volume for solid-phase peptide synthesis to 6,490 L. The company announced the opening of a plant for high-potency active pharmaceutical ingredients at Changzhou in June, and last month, the opening of a continuous manufacturing plant at the site.